– Aaronson N.K. et al., J Natl Cancer Inst 1993; 85 (5): 365–76
– AGO-Leitlinien 2018 der Kommission Mamma der AGO der DGGG;
www.ago-online.de/fileadmin/downloads/leitlinien/mamma/2018-03/Gesamt_deutsch/Alle_aktuellen_Empfehlungen_2018.pdf
– Allen R.J., Treece P.: Deep inferior epigastric perforator flap for breast reconstruction. Ann Plast Surg 1994; 32: 32–38
– Allred D.C., Anderson S.J., Paik S. et al.: Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP Protocol B-24. J Clin Oncol 2012. doi: 10.1200/JCO.2010.34.0141
– Alsaker M.D., Janszky I., Opdahl S., Vatten L.J., Romundstad P.R.: Weight change in adulthood and risk of postmenopausal breast cancer: the HUNT study of Norway. Br J Cancer 2013; 109 (5): 1310–7
– André F. et al.: Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929–1940
– Anne N., Pallapothu R.: Lymphoma of the breast: a mimic of inflammatory breast cancer. World J Surg Oncol 2011; 9: 125. doi: 10.1186/1477-7819-9-125
– AWMF – Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms; Version 4.3 – Februar 2020, AWMF-Registernummer: 032-045OL;
www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom
– Badwe R., Lancet Oncol 2015; 16 (13): 1380–1388
– Barrio A.V., Clark B.D., Goldberg J.I. et al.: Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol 2007; 14: 2961–2970
– Bartelink H. et al., Lancet Oncol 2015; 16 (1): 47–56
– Bartlett F.R. et al., Radiother Oncol 2015; 114 (1): 66–72
– Barton S.R., Smith I.E., Kirby A.M., Ashley S., Walsh G., Parton M.: The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer 2011; 47: 2099–2106. doi: 10.1016/j.ejca.2011.05.010
– Behranwala K.A., Nasiri N., Abdullah N., Trott P.A., Gui G.P.: Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome. Eur J Surg Oncol 2003; 29 (4): 386
– Bjelic-Radisic V. et al., Ann Oncol 2020; 31 (2): 283–288
– Boughey J.C. et al.: Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310 (14): 1455–61
– Boughey J.C., Bedrosian I., Meric-Bernstam F. et al.: Comparitive analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 2006; 203: 475–480
– Budach W. et al., Radiother Oncol 2015; 10: 258
– Burstein et al.: Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol 2019; 37 (5): 423–438
– Caliskan M. et al., Breast Cancer Res Treat 2008; 112 (3): 513–21
– Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490 (7418): 61
– Caudle A.S. et al., J Clin Oncol 2016; 34 (10): 1072–8
– Chao X. et al., BMC Cancer 2019; 19 (372)
– Choi N. et al., Clin Breast Cancer 2019; 19 (5): 345–353
– Clement Z. et al.: Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials. Gland Surg 2018; 7: 449–457
– Colditz G.A., Frazier A.L.: Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev 1995; 4 (5): 567
– Colditz G.A., Rosner B.: Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 2000; 152 (10): 950
– Confavreux C., Lurkin A., Mitton N. et al.: Sarcomas and malignant phyllodes tumours of the breas–a retrospective study. Eur J Cancer 2006; 42: 2715–2721
– Cortes J. et al., J Clin Oncol 2020; 38 (15, Suppl.): 1000–1000
– Darby S. et al., Lancet 2011; 378 (9804): 1707–16
– Dawood S., Merajver S.D., Viens P. et al.: International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011; 22: 515–523. doi:10.1093/annonc/mdq345
– Dayhim F., Wilkins E.G.: The impact of Pfannenstiel scars on TRAM flap complications. Ann Plast Surg 2004; 53: 432–435
– Depla A.L. et al., Eur J Cancer 2014; 50 (10): 1779–1788
– Deurloo E.E., Sriram J.D., Teertstra H.J. et al.: MRI of the breast in patients with DCIS to exclude the presence of invasive disease. Eur Radiol 2012. doi:10.1007/s00330-012-2394-5
– Dominici L.S. et al., Cancer 2010; 116 (12): 2884–9
– Dominici L.S., Lester S., Liao G.S. et al.: Current surgical approach to Paget’s disease. Am J Surg 2011. doi:10.1016/j.amjsurg.2011.07.010
– Donker M. et al., Lancet Oncol 2014; 15 (12): 1303–1310
– Dubsky P., Brase J.C., Jakesz R. et al.: The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2– breast cancer patients. Br J Cancer 2013; 109 (12): 2959–64
– Durkan B. et al., Am Surg 2013; 79 (10): 1009–12
– EBCTCG – Early Breast Cancer Trialists’ Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–717
– Emaus M.J. et al.: Weight change in middle adulthood and breast cancer risk in the EPIC-PANACEA study. Int J Cancer 2014; 135 (12): 2887–99
– Fallowfield L. et al., J Clin Oncol 2004; 22 (21): 4261–71
– Fastner G. et al., Eur J Cancer 2020; 127: 12–20
– Fastner G. et al., Radiother 2013; 108 (2): 279–86
– Finn R.S. et al.: Palbociclib and letrozole in advanced breast cancer. N Eng J Med 2016; 375: 1925–36
– Fisher B., Dignam J., Wolmark N. et al.: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993–2000. doi: 10.1016/S0140-6736(99)05036-9
– Forbes J.F. et al.: Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet 2016; 387 (10021): 866–873
– Galimberti V. et al., Eur J Surg Oncol 2014; 40 (10): 1203–8
– Gentilini O., Cremonesi M., Toesca A. et al.: Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Imaging 2010; 37: 78–83
– German G., Steinau H.U.: Breast reconstruction with the extended latissimus dorsi flap. Plast Reconstr Surg 1996; 97: 519–526
– Ghareeb E. et al., Am J Clin Oncology 2016; 39 (5): 463–467
– Gianni L. et al., San Antonio Breast Cancer Symposium Abstract 2019; Abstr. GS3-04
– Giuliano A.E., Hunt K.K., Ballman K.V. et al.: Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305: 569–575. doi: 10.1001/jama.2011.90
– Goetz M.P. et al.: MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35 (32): 3638–3646; doi: 10.1200/JCO.2017.75.6155
– Gram I.T., Park S.Y., Kolonel L.N., Maskarinec G., Wilkens L.R., Henderson B.E., Le Marchand L.: Smoking and Risk of Breast Cancer in a Racially/ Ethnically Diverse Population of Mainly Women Who Do Not Drink Alcohol: The MEC Study. Am J Epidemiol 2015; 182 (11): 917–25
– Gray R. et al. and Early Breast Cancer Trialists‘ Collaborative Group, SABCS 2018; Abstr. GS3-03
– Hagelstein V. et al., Ann Oncol 2016; 27 (12): 2294–2299
– Hahn K. et al.: Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107: 1219–1226
– Hamer J. et al., Support Care Cancer 2017; 25 (2) :409–419
– Harris L.N., Ismaila N., McShane L.M.: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34 (10): 1134
– Haviland J.S. et al., Lancet Oncol 2013; 4 (11): 1086–1094
– Haviland J.S. et al., Radiother Oncol 2016; 121 (3): 420–423
– Heller L., Feledy J.A. Chang D.W.: Strategies and options for free TRAM flap breast reconstruction in patients with midline abdominal scars. Plast Reconstr Surg 2005; 116: 753–759
– Hennessy B.T., Krishnamurthy S., Giordano S., Buchholz T.A., Kau S.W., Duan Z., Valero V., Hortobagyi G.N.: Squamous cell carcinoma of the breast. J Clin Oncol 2005; 23 (31): 7827
– Holland R., Peterse J.L., Millis R.R. et al., Semin Diagn Pathol 1994; 11: 167
– Holmström H.: The free abdominoplasty flap and its use in breast reconstruction: an experimental study and clinical case report. Scand J Plast Reconstr Surg 1979; 13: 423–437
– Hortobagyi G.N. et al.: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018; 29 (7): 1541–1547
– Horwitz S.M. et al., J Natl Compr Cancer Netw 2018; 16 (2): 123–135
– Houssami N., Ciatto S., Turner R.M., Cody H.S. III., Macaskill P.: Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Ann Surg 2011; 254 (2): 243–251. doi:10.1097/ SLA.0b013e31821f1564
– Hughes K.S. et al., JCO 2013; 31 (19): 2382–7
– Hwang E.S., Kinkel K., Esserman L.J., Lu Y., Weidner N., Hylton N.M.: Magnetic resonance imaging in patients diagnosed with ductal carcinomain- situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol 2003; 10: 381–388
– Im S.-A. et al.: Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019; 381 (4): 307–316
– Jaiyesimi I.A., Buzdar A.U., Hortobagyi G.: Inflammatory breast cancer: a review. J Clin Oncol 1992; 10 (6): 1014
– Jansen M.P., Sieuwerts A.M., Look M.P. et al.: HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol 2007; 25 (6): 662
– Jensen R.E. et al., J Oncol Pract 2014; 10 (4): e215–22
– Jiang Z. et al.: MONARCHplus: A phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+/HER2– advanced breast cancer (ABC). Ann Oncol 2019; 30 (5): V863
– Kaur P., Kiluk J.V., Meade T. et al.: Sentinel lymph node biopsy in patients with previous ipsilateral complete axillary lymph node dissection. Ann Surg Oncol 2011; 18: 727–732. doi: 10.1245/s10434-010-1120-2
– Keshaviah A., Dellapasqua S., Rotmensz N. et al.: CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: A combined analysis of seven international breast cancer study group trials. Ann Oncol 2007; 18: 701–708
– Kiluk J.V., Lee M.C., Park C.K. et al.: Male breast cancer: management and follow-up recommendations. Breast J 2011; 17: 503–509
– Krug D. et al., Strahlenther Onkol 2018; 194 (7): 607–618
– Kuehn T. et al., Cancer 2005; 103 (3): 451–61
– Kuehn T. et al., Lancet Oncol 2013; 14 (7): 609–18
– Kunkler I.H. et al., Lancet Oncol 2015; 16: 266–73
– Kunkler I.H., SABCS 2020; Abstr. GS2–03
– Kyndi M. et al., Radiother Oncol 2009; 90 (1): 74–9
– Lagios M.D., Margolin F.R., Westdahl P.R., Rose M.R.: Cancer 1989; 63: 618
– Lazzeroni M. et al., Cancer Treat Rev 2017; 55: 1–9
– Litton J.K. et al.: Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018; 379: 753–763
– Liu G.F., Yang Q., Haffty B.G., Moran M.S.: Clinical-pathologic features and long-term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy. Int J Radiat Oncol Biol Phys 2009; 75 (5): 1304
– Loibl S. et al.: Neoadjuvant treatment of breast cancer-Clinical and research perspective. Breast 2015; 24 (Suppl. 2): S73–7
– Lovrics P.J., Goldsmith C.H., Hodgson N. et al.: A multicentered, randomized, controlled trial comparing radioguided seed localization to standard wire localization for nonpalpable, invasive and in situ breast carcinomas. Ann Surg Oncol 2011; 18: 3407–3414. doi:10.1245/ s10434-011-1699-y
– Lyman G.H. et al.: Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014; 32 (13): 1365–83
– Mamounas E.P., Brown A., Anderson S., Smith R., Julian T., Miller B. et al.: Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005; 23: 2694–2702. doi: 10.1200/ JCO.2005.05.188
– Masuda N. et al., NEJM 2017; 376: 2147–2159
– McCormack V.A., dos Santos Silva I.: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15 (6): 1159
– McCraw J., Papp C.: The fleur-de-lis autogenous Latissimus dorsi myocutaneous flap breast reconstruction. Presented before the Annual Meeting of the American Association of Plastic Surgeons 1989, Scottsdale
– McGale P. et al., Lancet 2014; 383 (9935): 2127–2135
– Meattini I. et al., Eur J Cancer 2017; 76: 17–26
– Meattini I. et al., SABCS 2019; Abstr. GS4–06
– Megdal S.P., Kroenke C.H., Laden F., Pukkala E., Schernhammer E.S.: Night work and breast cancer risk: a systematic review and meta-analysis. Eur
J Cancer 2005; 41 (13): 2023
– Mir O. et al.: Taxanes during pregnancy a systematic review. Ann Oncol 2010; 21 (2): 425–426
– Modi S. et al.: Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020; 382: 601–21
– Moran M.S, et al.: Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer.
J Clin Oncol 2014; 32: 1507–15
– Morrow M. et al.: Society of Surgical Oncology – American Society for Radiation Oncology – American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. J Clin Oncol 2016
– Murthy R.K. et al.: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. NEJM 2020; 382 (7): 597–609
– Murthy V., Chamberlain R.S.: Defining a place for nipple sparing mastectomy in modern breast care: an evidence based review. Breast J 2012. doi: 10.1111/j.1524-4741.2011.01220.x
– Myierzinska J. et al., Eur J Cancer 2020; 125: 69–82
– Narod S.A. et al., JAMA 2015; 1 (7): 888–896
– Narod S.A., Iqbal J., Giannakeas V. et al.: Breast cancer mortality after a diagnosis of ductal carcinomain situ. JAMA Oncol 2015; 1: 888–896
– Nilsson C. et al., Radiother Oncol 2015; 114 (1): 50–5
– Offerson B.V. et al., Radiother Oncol 2016; 118 (1): 205–8
– Ong C.T. et al., Ann Surg Oncol 2018; 25 (8): 2249–2260
– Owen J.R. et al., Lancet Oncol 2006; 7 (6): 467–71
– Parker J.S., Mullins M., Cheang M.C. et al.: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27 (8): 1160
– Perou C.M., Sørlie T., Eisen M.B. et al.: Molecular portraits of human breast tumours. Nature 2000; 406 (6797): 747
– Petermann F. et al., Zeitschrift für Psychiatrie, Psychologie und Psychotherapie 2011; 59: 251–253
– Petru E., Fink D., Köchli O., Loibl S. (Hrsg.): Praxisbuch Gynäkologische Onkologie. 5. Auflage, Springer, Heidelberg, 2019
– Piroth et al., Strahlenther Onkol 2021; 197 (1): 1–7
– Poortmans P.M. et al., NEJM 2015; 373: 317–327
– Robson M. et al.: Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017; 377: 523–533
– Romics L. Jr., Chew B.K., Weiler-Mithoff E. et al.: Ten-year follow-up of skin-sparing mastectomy followed by immediate breast reconstruction. Br J Surg 2012. doi: 10.1002/bjs.8704
– Schettini F. et al.: Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. J Natl Cancer Inst 2020; 112 (11): 1089–1097
– Schmid P et al.: Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379: 2108–2121
– Schmid P. et al.: Phase III KEYNOTE-522: Pembrolizumab Benefits Outcome in Neoadjuvant, Adjuvant Settings in Triple-Negative Breast Cancer. San Antonio Breast Cancer Symposium 2019; Abstr. GS3-03
– Sedlmayer F. et al., Strahlenther Onkol 2013; 189 (10): 825–33
– Shaitelmann S.F. et al., JCO 2018; 36 (35): 3495–3503
– Sher T., Hennessy B.T., Valero V. et al.: Primary angiosarcomas of the breast. Cancer 2007; 110: 173–178
– Siegel R.L., Miller K.D., Jemal A.: Cancer statistics, 2016. CA Cancer J Clin 2016; 66 (1): 7
– Silverstein M.J., Poller D.N., Waisman J.R. et al., Lancet 1995; 345: 1154
– Silverstein M.J., Waisman J.R., Gamagami P., Gierson E.D., Colburn W.J., Rosser R.J., Gordon P.S., Lewinsky B.S., Fingerhut A.: Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990; 66 (1): 102
– Slamon D.J. et al.: Phase III randomized study of ribociclib and fulvestrant in hormone-receptor positive, HER2 neu negative advanced breast cancer MONALEESA-3. J Clin Oncol 2018; 36 (24): 2465–2472. doi: 10.1200/JCO 2018.78.9909
– Sledge G.W et al.: The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy – MONARCH 2: a randomized clinical trial. JAMA Oncol 2020; 6( 1): 116
– Smith T.J. et al.: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24 (19): 3187–3205
– Sparano J.A., Gray R.J., Makower D.F. et al.: Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2015; 373 (21): 2005
– Statistik Austria: www.statistik.at/web_de/statistiken/menschen_und_gesellschaft/gesundheit/krebserkrankungen/brust/index.html; letzte Änderung am 21. 7. 2020
– Stranzl H. et al., Radiother Oncol 1999; 53 (1): 29–35
– Stranzl H. et al., Strahlenther Onkol 2004; 180 (10): 623–628
– Stranzl H. et al., Strahlenther Onkol 2006; 182 (10): 583–588
– Stranzl H. et al., Strahlenther Onkol 2008; 184 (7): 354–358
– Stranzl H. et al., Strahlenther Onkol 2009; 185 (3): 155–60
– Strnad V. et al., Lancet 2016; 387 (10015): 229–38
– Swain S.M., Jeong J.H., Geyer C.E. Jr., et al.: Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362 (22): 2053
– Tee S.R. et al., Breast J Surg 2018; 05 (12): 1541–1552
– Thorsen L.B.J. et al., JCO 2016; 34 (4): 314–20
– Thurman S.A., Schnitt S.J., Connolly J.L., Gelman R., Silver B., Harris J.R., Recht A.: Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma. Int J Radiat Oncol Biol Phys 2004; 59 (1): 152
– Tseng W.H., Ann Surg Oncol 2011; 18 (1): 94–103
– Turner N.C. et al.: Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 2018; 379 (20): 1926–1936
– Van Mackelenberg M., SABCS 2019; Abstr. GS1–07
– Van Zee K.J., Subhedar P., Olcese C., Patil S,. Morrow M.: Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg 2015; 262 (4): 623–31
– Varadarajan R., Edge S.B., Yu J., Watroba N., Janarthanan B.R.: Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology 2006; 71: 456–459. doi: 10.1159/000107111
– Vashi R., Hooley R., Butler R., Geisel J., Philpotts L.: Breast Imaging of the Pregnant and Lactating Patient: Imaging Modalities and Pregnancy-Associated Breast Cancer. Am J Roentgen 2013; 200: 321–328
– Veronesi U. et al., Lancet Oncology 2013; 14 (13): 1269–1277
– Viani G.A. et al., Breast 2014; 23 (6): 749–53
– Vicini F.A. et al., Lancet 2019; 394 (10215): 2155–2164
– Wang S.L. et al. Lancet Oncol 2019; 20 (3): 352–360
– Weaver D.L., Ashikaga T., Krag D.N. et al.: Effect of Occult Metastases on Survival in Node-Negative Breast Cancer. New Engl J Med 2011; 364:
412–421. doi: 10.1056/Nejmoa1008108
– Whelan T.J. et al., NEJM 2010; 362: 513–520
– Whelan T.J. et al., NEJM 2015; 373: 307–316
– Whelan T.J., Lancet 2019; 394 (10215): 2165–2172
– Wittekind et al.: TNM: Klassifikation maligner Tumoren. 7. Auflage. Wiley- VCH Verlag, Weinheim 2010; 3. korrigierter Nachdruck 2011
– Wolf I., Sadetzki S., Catane R., Karasik A., Kaufman B.: Diabetes mellitus and breast cancer. Lancet Oncol 2005; 6 (2): 103
– Wood-Dauphinee S. et al., Can J Rehabil 1992; 6: 3–12
– Woodward W.A. et al., Int J Radiat Oncol Biol Phys 2017; 99 (4): 777–783
– Zurl B. et al., Strahlenther Onkol 2010; 186 (3): 157–62
